What does Tejnaksh Health. do?

Tejnaksh Healthcare Ltd is a micro-cap company in the healthcare services industry, incorporated in 2008 and publicly listed since 2015, with recent quarterly net sales of 3 Cr and net profit of 1 Cr as of March 2025. Key financial metrics include a market cap of Rs 45 Cr, P/E ratio of 19.00, and a return on equity of 9.15%.

Overview:<BR>Tejnaksh Healthcare Ltd operates in the healthcare services industry and is classified as a micro-cap company.<BR><BR>History:<BR>Tejnaksh Healthcare Ltd was incorporated in 2008 as "Tejnaksh Healthcare Private Limited" and later converted to a public limited company in 2015. The most recent quarterly results report net sales and net profit for March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 3 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 45 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 19.00 <BR>Industry P/E: 54 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.04 <BR>Return on Equity: 9.15% <BR>Price to Book: 1.72 <BR><BR>Contact Details:<BR>Address: A 601 Floor No 6 Kailash, Business Park Veer SavarkarMar Mumbai Maharashtra : 400079 <BR>Email: cs.tejnaksh@gmail.com <BR>Website: http://www.tejnaksh.com

What is the bonus history of the Tejnaksh Health.?

Tejnaksh Health's recent bonus history includes a 36:10 bonus issued on April 26, 2018, with a record date of April 28, 2018, and a previous 1:1 bonus issued on March 8, 2017, with a record date of March 9, 2017.

Tejnaksh Health has a notable bonus history. The most recent bonus issue was a 36:10 ratio, which was announced with an ex-date of April 26, 2018, and a record date of April 28, 2018. Prior to that, the company issued a bonus with a 1:1 ratio, which had an ex-date of March 8, 2017, and a record date of March 9, 2017. If you have any more questions about Tejnaksh Health or its financial activities, feel free to ask!

Has Tejnaksh Health. declared dividend?

No Dividend History Available

Who are the peers of the Tejnaksh Health.?

Tejnaksh Health's peers include Syngene Intl., Dr Lal Pathlabs, and Poly Medicure, among others. In terms of performance, Poly Medicure leads with a 1-year return of 24.29%, while Tejnaksh Health has a return of -18.17%.

Peers: The peers of Tejnaksh Health are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., GKB Ophthalmics, KMS Medisurgi, Medinova Diagno., Amkay Products.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs and Amkay Products, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and the rest have Below Average management risk. Growth ratings show Excellent growth at Dr Lal Pathlabs, while Average growth is found at Poly Medicure, Indegene, and the rest, with Below Average growth at Syngene Intl., Vijaya Diagnost., Tejnaksh Health., GKB Ophthalmics, KMS Medisurgi, and Amkay Products. In terms of Capital Structure, Excellent ratings are seen at Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., and the rest have Good or do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Poly Medicure at 24.29%, while Amkay Products has the lowest at -34.33%. Tejnaksh Health's 1-year return is -18.17%, which is better than Amkay Products but worse than Poly Medicure. Additionally, the peers with negative six-month returns include Syngene Intl., Poly Medicure, Vijaya Diagnost., Amkay Products, and Transgene Biotek.

Is Tejnaksh Health. overvalued or undervalued?

As of July 30, 2024, Tejnaksh Health is considered very attractive and undervalued with a PE ratio of 19.05, strong growth potential indicated by a PEG ratio of 0.54, and favorable comparisons to peers like Max Healthcare and Apollo Hospitals, despite a challenging year with a stock return of -11.6%.

As of 30 July 2024, the valuation grade for Tejnaksh Health has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently assessed as undervalued, with a price-to-earnings (PE) ratio of 19.05, an EV to EBITDA ratio of 10.84, and a PEG ratio of 0.54, which suggests strong growth potential relative to its price. <BR><BR>In comparison to its peers, Tejnaksh Health stands out favorably; for instance, Max Healthcare is deemed very expensive with a PE ratio of 100.29, while Apollo Hospitals has a PE ratio of 69.03. The company's solid return on capital employed (ROCE) of 12.73% and return on equity (ROE) of 9.15% further reinforce its attractiveness. Despite a challenging year with a stock return of -11.6% compared to the Sensex's 7.62%, the current valuation metrics suggest that Tejnaksh Health presents a compelling investment opportunity.

What is the technical trend for Tejnaksh Health.?

As of June 6, 2025, Tejnaksh Health's trend has shifted to sideways, with mixed indicators showing mild bullish momentum on the weekly MACD and KST, while daily moving averages and Bollinger Bands suggest a consolidation phase without a clear directional bias.

As of 6 June 2025, the technical trend for Tejnaksh Health has changed from mildly bearish to sideways. The current stance is neutral, with a mix of indicators influencing the outlook. The weekly MACD and KST are both mildly bullish, suggesting some positive momentum, while the daily moving averages indicate a mildly bearish trend. The Bollinger Bands show a mildly bearish stance on the weekly chart and sideways on the monthly chart. Overall, the lack of strong signals from the RSI and Dow Theory indicates a consolidation phase without a clear directional bias.

Who are in the management team of Tejnaksh Health.?

As of March 2022, the management team of Tejnaksh Health includes Ashish Vishwas Rawandale (Chairman/Executive Director), Preeti Ashish Rawandale (Non-Executive Director), Kiran Madhavrao Pawar, Vikramsinh Satish Khatal Patil, and Suhas Vasantrao Thorat (all Independent Non-Executive Directors), and Sanjay Bhikajirao Khatak (Non-Executive Director). These individuals guide the company's governance and strategic direction.

As of March 2022, the management team of Tejnaksh Health includes the following individuals:<BR><BR>1. Ashish Vishwas Rawandale - Chairman / Executive Director<BR>2. Preeti Ashish Rawandale - Non-Executive & Non-Independent Director<BR>3. Kiran Madhavrao Pawar - Independent Non-Executive Director<BR>4. Vikramsinh Satish Khatal Patil - Independent Non-Executive Director<BR>5. Sanjay Bhikajirao Khatak - Non-Executive & Non-Independent Director<BR>6. Suhas Vasantrao Thorat - Independent Non-Executive Director<BR><BR>These members contribute to the governance and strategic direction of the company.

Who are the top shareholders of the Tejnaksh Health.?

The top shareholder of Tejnaksh Health is Ashish Vishwas Rawandale, holding 38.15%. The highest public shareholder is Sheetal Utkarsh Rawandale at 1.45%, with individual investors owning a total of 23.58%.

The top shareholders of Tejnaksh Health include the promoters, with Ashish Vishwas Rawandale holding the largest share at 38.15%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Sheetal Utkarsh Rawandale, who owns 1.45%. Additionally, individual investors collectively hold 23.58% of the company.

How big is Tejnaksh Health.?

As of 24th July, Tejnaksh Healthcare Ltd has a market capitalization of 40.00 Cr, with net sales of 12.89 Cr and a net profit of 2.37 Cr over the latest four quarters. The company reported shareholder's funds of 23.57 Cr and total assets of 31.35 Cr for the annual period ending March 2024.

As of 24th July, Tejnaksh Healthcare Ltd has a market capitalization of 40.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Tejnaksh Healthcare Ltd reported Net Sales of 12.89 Cr and a Net Profit of 2.37 Cr.<BR><BR>For the latest annual period ending March 2024, the company had Shareholder's Funds amounting to 23.57 Cr and Total Assets of 31.35 Cr.

When is the next results date for Tejnaksh Health.?

Tejnaksh Health will announce its results on 14 August 2025.

Tejnaksh Health is scheduled to declare its results on 14 August 2025.

Are Tejnaksh Health. latest results good or bad?

Tejnaksh Healthcare's latest results for June 2025 are unfavorable, with net sales down 15.38%, operating profit at a five-quarter low, and declining earnings per share, indicating significant challenges in profitability and operational efficiency.

Tejnaksh Healthcare's latest financial results for the quarter ending June 2025 indicate a challenging period for the company. The performance has been flat, with several key metrics showing significant declines compared to the same quarter last year.<BR><BR>Net sales have decreased by 15.38%, a stark contrast to the previous year's growth. The operating profit (PBDIT) has also fallen to Rs 0.60 crore, marking the lowest figure in five quarters, and the profit before tax (PBT) has dropped to Rs 0.20 crore, reflecting a negative trend in profitability. Earnings per share (EPS) have declined to Rs 0.12, which is again the lowest in five quarters.<BR><BR>Additionally, the debtors turnover ratio has decreased to 6.97 times, indicating a slowdown in the company's ability to manage its debts effectively. Overall, these results suggest that Tejnaksh Healthcare is facing significant challenges in maintaining profitability and operational efficiency, which can be viewed as unfavorable performance indicators.

Why is Tejnaksh Health. falling/rising?

As of 02-Dec, Tejnaksh Healthcare Ltd's stock price is rising slightly to Rs 16.58, but it has underperformed significantly over the year with a 26.34% decline. The stock is also trading below key moving averages and has seen reduced investor interest, indicating a bearish trend overall.

As of 02-Dec, Tejnaksh Healthcare Ltd's stock price is rising, currently at Rs 16.58, reflecting an increase of Rs 0.13 or 0.79%. This rise comes after the stock experienced two consecutive days of decline, indicating a potential trend reversal. Additionally, the stock has outperformed its sector by 1.02% today, which may contribute to the positive momentum.<BR><BR>Despite this short-term increase, the stock has been underperforming over longer periods, with a year-to-date decline of 26.34% compared to a 8.96% rise in the Sensex. Furthermore, the stock is currently trading lower than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a generally bearish trend over time. <BR><BR>Investor participation has also decreased, with a significant drop in delivery volume by 51.33% against the 5-day average, indicating reduced interest from investors. The stock is close to its 52-week low, being only 3.38% away from Rs 16.02. <BR><BR>In summary, while there is a slight rise in the stock price today, it is essential to consider the broader context of its ongoing underperformance and declining investor participation.

Which are the latest news on Tejnaksh Health.?

Should I buy, sell or hold Tejnaksh Health.?

How has been the historical performance of Tejnaksh Health.?

Tejnaksh Health's historical performance shows fluctuating net sales and profits, with a decline from Mar'19 to Mar'20, followed by recovery; net sales rose to 12.90 Cr in Mar'25 from 11.73 Cr in Mar'23, but cash flow from operations dropped to 0.00 Cr in Mar'25, indicating challenges despite improved profits.

Answer:<BR>The historical performance of Tejnaksh Health shows a fluctuating trend in net sales and profits over the years, with a notable decline from Mar'19 to Mar'20, followed by a gradual recovery. <BR><BR>Breakdown:<BR>Tejnaksh Health's net sales increased from 11.73 Cr in Mar'23 to 12.90 Cr in Mar'25, reflecting a positive growth trend. However, this is a decrease from the peak of 19.76 Cr in Mar'19. The total operating income also followed a similar pattern, rising to 12.90 Cr in Mar'25 from 11.73 Cr in Mar'23. The company's total expenditure, excluding depreciation, has increased from 8.04 Cr in Mar'23 to 8.82 Cr in Mar'25, indicating rising operational costs. Operating profit (PBDIT) improved to 4.48 Cr in Mar'25 from 4.00 Cr in Mar'23, while profit before tax rose to 3.19 Cr in Mar'25 from 2.51 Cr in Mar'23. The profit after tax also saw an increase, reaching 2.23 Cr in Mar'25 compared to 1.79 Cr in Mar'23. On the balance sheet, total liabilities decreased from 31.23 Cr in Mar'23 to 30.31 Cr in Mar'25, while total assets also slightly declined from 31.23 Cr to 30.31 Cr in the same period. The company's cash flow from operating activities showed a significant drop to 0.00 Cr in Mar'25 from 2.00 Cr in Mar'23, indicating challenges in generating cash from operations. Overall, while Tejnaksh Health has shown some recovery in sales and profits, it faces pressures on cash flow and rising costs.